title: Pharmacological approaches in celiac disease.
abstract: Celiac disease is an autoimmune enteropathy triggered by the ingestion of gluten, characterized by immune responses toward gluten constituents and the autoantigen transglutaminase 2. The only current treatment available for celiac disease is a gluten-free diet, however there are a plethora of therapies in development for the treatment of celiac disease (e.g. vaccine), management of symptoms while consuming gluten (e.g. Necator americanus) or adjuvant therapies in conjunction with the gluten-free diet (e.g. larazotide acetate). Current approaches in development target barrier function, immune responses, detoxifying gluten or sequestering gluten. Developing therapies include those targeting environmental factors, such as the microbiota or proteases.
authors.affiliation: Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
authors.forename: Justin L
authors.initials: JL
authors.lastname: McCarville
authors.affiliation: Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.
authors.forename: Alberto
authors.initials: A
authors.lastname: Caminero
authors.affiliation: Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada. Electronic address: verdue@mcmaster.ca.
authors.forename: Elena F
authors.initials: EF
authors.lastname: Verdu
mesh_terms: D000723:Ancylostomatoidea; D000818:Animals; D002446:Celiac Disease / Q000178:diet therapy / Q000188:drug therapy*; D055050:Diet, Gluten-Free; D053492:Elafin / Q000494:pharmacology* / Q000627:therapeutic use*; D057487:Enzyme Therapy / Q000379:methods; D019204:GTP-Binding Proteins / Q000037:antagonists & inhibitors*; D005983:Glutens / Q000009:adverse effects* / Q000187:drug effects / Q000378:metabolism; D006680:HLA Antigens / Q000187:drug effects; D006801:Humans; D008954:Models, Biological; D019936:Probiotics / Q000627:therapeutic use*; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects; D011503:Transglutaminases / Q000037:antagonists & inhibitors*
chemical_list: C583420:CCX282-B; D053492:Elafin; D006680:HLA Antigens; D013449:Sulfonamides; D005983:Glutens; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D011503:Transglutaminases; D019204:GTP-Binding Proteins